{{Drugbox
| verifiedrevid = 442303628
| IUPAC_name = (E)-N'-(1-((2S,4S)-4-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)ethylidene)benzohydrazide
| image = Zorubicin.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 54083-22-6
| ATC_prefix = L01
| ATC_suffix = DB05
| ATC_supplemental =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V25F9362OP
|  PubChem = 9595290
|  ChemSpiderID = 7869436
|  StdInChI = 1S/C34H35N3O10/c1-15-28(38)20(35)12-23(46-15)47-22-14-34(44,16(2)36-37-33(43)17-8-5-4-6-9-17)13-19-25(22)32(42)27-26(30(19)40)29(39)18-10-7-11-21(45-3)24(18)31(27)41/h4-11,15,20,22-23,28,38,40,42,44H,12-14,35H2,1-3H3,(H,37,43)/b36-16+/t15-,20-,22-,23-,28+,34-/m0/s1
|  StdInChIKey = FBTUMDXHSRTGRV-ALTNURHMSA-N

<!--Chemical data-->
| chemical_formula =  
| C=34 | H=35 | N=3 | O=10 
| molecular_weight = 645.65 g/mol
| smiles = OC1=C(C(C4=C(C=CC=C4OC)C3=O)=O)C3=C(O)C2=C1[C@@H](O[C@]5([H])O[C@@H](C)[C@@H](O)[C@@H](N)C5)C[C@@](/[C@@](C)=N/NC(C6=CC=CC=C6)=O)(O)C2
}}

'''Zorubicin''' ([[International Nonproprietary Name|INN]]) is an [[anthracycline]].



{{Chemotherapeutic agents}}

[[Category:Anthracyclines]]
[[Category:Topoisomerase inhibitors]]
[[Category:Hydrazides]]
[[Category:Phenols]]
[[Category:Phenol ethers]]


{{antineoplastic-drug-stub}}